FMP
BiondVax Pharmaceuticals Ltd.
BVXV
NASDAQ
Inactive Equity
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
1.36 USD
0.01 (0.735%)
About
ceo
Mr. Amir Reichman M.B.A., M.Sc.
sector
Healthcare
industry
Biotechnology
website
https://www.biondvax.com
exchange
NASDAQ
Description
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
CIK
0001611747
ISIN
US09073Q1058
CUSIP
09073Q105
Address
Jerusalem BioPark Building
Phone
972 8 930 2529
Country
IL
Employee
33
IPO Date
May 12, 2015
Key Executives
